Sign InSummary
Tempest Therapeutics (TPST) has experienced a significant stock surge of 2880.41% after positive clinical trial results for its liver cancer treatment, leading analysts to recommend a Buy on the stock; however, with the stock being highly volatile and overbought, investors should exercise caution and be aware of upcoming news and events.
Fundamental Analysis
Tempest Therapeutics, Inc. (TPST) is a NASDAQ-listed, clinical-stage oncology company. As of its last close on October 11, 2023, the stock was priced at $7.15 with a striking rise of 2880.41%, displaying an exceptional intraday growth from $1.82 to a high of $7.59. The TPST stock also demonstrated strong momentum, departing from its 50-day moving average of $0.53 and its 200-day moving average of $1.40. Their market cap stands at around $95.27 million.
In terms of financial performance, TPST has an EPS of -$2 and a negative PE ratio of -3.57, indicating that they are not currently profitable and reflecting the risks common to clinical-stage pharmaceutical firms. Against a total of 13.32 million outstanding shares, the company showed a large trading volume of 157.69 million shares.
The company has recently attracted significant attention due to the positive outcomes of its randomized Phase 1b/2 clinical trial for the TPST-1120 drug candidate, a potential liver cancer treatment. This vital development is likely the driver behind TPST's drastic stock surge and may continue to influence the stock's trajectory in the near term.
Technical Analysis
The TPST stock's technical indicators give mixed signals. It has an exceptionally high RSI14 of 96, indicating that the stock might be overbought. On the contrary, the stock's MACD (3-month) is at -0.04823, showing a potentially bullish crossover from bearish territory. Given the highly volatile nature of the stock, characterized by an ATR (Average True Range) of 7.91, it is critical to set stop-loss limits, recommended here at $6.93.
Analyst Consensus and News Sentiment
The consensus is predominately in favor of a "Buy." Presumably, this optimism arises from the announcement of positive clinical trial results, which sent the stock soaring above the year's previous high of $9.77, and surpassed the year's low of $0.17 evidently.
In the news, TPST has generated considerable interest, primarily due to its promising clinical trial results. This surge in news sentiment could contribute to increased investor interest and potentially impact the stock's price in the short term.
Prediction and Evaluation
Based on the above data, TPST's stock is likely to maintain its strong momentum in the next trading day from October 12, 2023, and into the following week. However, given the stock's extreme volatility and overbought state, some pullback may occur.
In conclusion, acknowledging the potential of TPST's oncology treatment and considering recent positive clinical results, TPST stock can be classified as a "Buy" for investors with a high-risk tolerance who closely follow and understand the biotechnology sector. Nevertheless, it's important to note that TPST is a highly speculative stock due to its current unprofitable state and extreme volatility. Investors should remain observant of future news, especially the anticipated Earnings Announcement on November 6, 2023.
